Cargando…

Preferences for health outcomes associated with Group A Streptococcal disease and vaccination

BACKGROUND: A 26-valent Group A Streptococcus (GAS) vaccine candidate has been developed that may provide protection against pharyngitis, invasive disease and rheumatic fever. However, recommendations for the use of a new vaccine must be informed by a range of considerations, including parents'...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Grace M, Salomon, Joshua A, Gay, Charlene, Hammitt, James K
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848145/
https://www.ncbi.nlm.nih.gov/pubmed/20226042
http://dx.doi.org/10.1186/1477-7525-8-28
_version_ 1782179647662850048
author Lee, Grace M
Salomon, Joshua A
Gay, Charlene
Hammitt, James K
author_facet Lee, Grace M
Salomon, Joshua A
Gay, Charlene
Hammitt, James K
author_sort Lee, Grace M
collection PubMed
description BACKGROUND: A 26-valent Group A Streptococcus (GAS) vaccine candidate has been developed that may provide protection against pharyngitis, invasive disease and rheumatic fever. However, recommendations for the use of a new vaccine must be informed by a range of considerations, including parents' preferences for different relevant health outcomes. Our objectives were to: (1) describe parent preferences for GAS disease and vaccination using willingness-to-pay (WTP) and time trade-off (TTO) methods; and (2) understand how parents' implied WTP for a quality-adjusted life year (QALY) gained might vary depending on the particular health outcome considered (e.g. averted GAS disease vs. vaccine adverse events). METHODS: Telephone interviews were conducted with parents of children diagnosed with GAS pharyngitis at 2 pediatric practice sites in the Boston metropolitan area. WTP and TTO (trading parental longevity for child's health) questions for 2 vaccine and 4 disease-associated health states were asked using a randomly selected opening bid, followed by a 2(nd )bid and a final open-ended question about the amount willing to pay or trade. Descriptive analyses included medians and interquartile ranges for WTP and TTO estimates. The Wilcoxon signed-rank test was used to assess differences in WTP/QALY values for vaccine adverse events vs. disease states. RESULTS: Of 119 respondents, 100 (84%) and 96 (81%) provided a complete set of responses for WTP and TTO questions, respectively. The median WTP and discounted (at 3% per year) TTO values to avoid each health state were as follows: local reaction, $30, 0.12 days; systemic reaction, $50, 0.22 days; impetigo, $75, 1.25 days; strep throat, $75, 2.5 days; septic arthritis, $1,000, 6.6 days; and toxic shock syndrome, $3,000, 31.0 days. The median WTP/QALY was significantly higher for vaccine adverse events (~$60,000/QALY) compared to disease states ($18,000 to $36,000/QALY). CONCLUSIONS: Parents strongly prefer to prevent GAS disease in children compared to vaccine adverse events. However, implied WTP/QALY ratios were higher for the prevention of vaccine adverse events. Regret for errors of commission vs. omission may differ and should be considered by vaccine policymakers.
format Text
id pubmed-2848145
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28481452010-04-01 Preferences for health outcomes associated with Group A Streptococcal disease and vaccination Lee, Grace M Salomon, Joshua A Gay, Charlene Hammitt, James K Health Qual Life Outcomes Research BACKGROUND: A 26-valent Group A Streptococcus (GAS) vaccine candidate has been developed that may provide protection against pharyngitis, invasive disease and rheumatic fever. However, recommendations for the use of a new vaccine must be informed by a range of considerations, including parents' preferences for different relevant health outcomes. Our objectives were to: (1) describe parent preferences for GAS disease and vaccination using willingness-to-pay (WTP) and time trade-off (TTO) methods; and (2) understand how parents' implied WTP for a quality-adjusted life year (QALY) gained might vary depending on the particular health outcome considered (e.g. averted GAS disease vs. vaccine adverse events). METHODS: Telephone interviews were conducted with parents of children diagnosed with GAS pharyngitis at 2 pediatric practice sites in the Boston metropolitan area. WTP and TTO (trading parental longevity for child's health) questions for 2 vaccine and 4 disease-associated health states were asked using a randomly selected opening bid, followed by a 2(nd )bid and a final open-ended question about the amount willing to pay or trade. Descriptive analyses included medians and interquartile ranges for WTP and TTO estimates. The Wilcoxon signed-rank test was used to assess differences in WTP/QALY values for vaccine adverse events vs. disease states. RESULTS: Of 119 respondents, 100 (84%) and 96 (81%) provided a complete set of responses for WTP and TTO questions, respectively. The median WTP and discounted (at 3% per year) TTO values to avoid each health state were as follows: local reaction, $30, 0.12 days; systemic reaction, $50, 0.22 days; impetigo, $75, 1.25 days; strep throat, $75, 2.5 days; septic arthritis, $1,000, 6.6 days; and toxic shock syndrome, $3,000, 31.0 days. The median WTP/QALY was significantly higher for vaccine adverse events (~$60,000/QALY) compared to disease states ($18,000 to $36,000/QALY). CONCLUSIONS: Parents strongly prefer to prevent GAS disease in children compared to vaccine adverse events. However, implied WTP/QALY ratios were higher for the prevention of vaccine adverse events. Regret for errors of commission vs. omission may differ and should be considered by vaccine policymakers. BioMed Central 2010-03-12 /pmc/articles/PMC2848145/ /pubmed/20226042 http://dx.doi.org/10.1186/1477-7525-8-28 Text en Copyright ©2010 Lee et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Lee, Grace M
Salomon, Joshua A
Gay, Charlene
Hammitt, James K
Preferences for health outcomes associated with Group A Streptococcal disease and vaccination
title Preferences for health outcomes associated with Group A Streptococcal disease and vaccination
title_full Preferences for health outcomes associated with Group A Streptococcal disease and vaccination
title_fullStr Preferences for health outcomes associated with Group A Streptococcal disease and vaccination
title_full_unstemmed Preferences for health outcomes associated with Group A Streptococcal disease and vaccination
title_short Preferences for health outcomes associated with Group A Streptococcal disease and vaccination
title_sort preferences for health outcomes associated with group a streptococcal disease and vaccination
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848145/
https://www.ncbi.nlm.nih.gov/pubmed/20226042
http://dx.doi.org/10.1186/1477-7525-8-28
work_keys_str_mv AT leegracem preferencesforhealthoutcomesassociatedwithgroupastreptococcaldiseaseandvaccination
AT salomonjoshuaa preferencesforhealthoutcomesassociatedwithgroupastreptococcaldiseaseandvaccination
AT gaycharlene preferencesforhealthoutcomesassociatedwithgroupastreptococcaldiseaseandvaccination
AT hammittjamesk preferencesforhealthoutcomesassociatedwithgroupastreptococcaldiseaseandvaccination